Lipid Nanoparticles Immunogenicity & Toxicity | December 6-8, 2022
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been […]
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been […]
The LNP Development Europe Summit is the only European conference solely dedicated to LNP formulation and process development to enable seamless scale-up, keeping GMP compliance and manufacturing. Given the rapid developments in the […]
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted […]
What You Should Know: – H1, launches an update to its flagship product, HCP Universe, the daily resource for global medical affairs and medical science […]
What You Should Know: – The index of Healthcare & Life Science equities tracked by Stout was down 16.8% in Q2 2022, which was in […]
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no […]
Richard Marcil, Chief Customer Officer at ConversationHEALTH Simon Johns, Director of Medical Information and Marketed Product Safety at IQVIA Life science organizations field a wide […]
Dan UpDyke, Strategic Marketing Manager Life Sciences at Rockwell Automation The ability to navigate constant disruption is a prerequisite for success in today’s life science […]
What You Should Know: – Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for […]
When creating engagement plans for individual Digital Key Opinion Leaders (DOLs), it’s best to look at a range of data-led metrics about each DOL to […]
SAE Media Group’s 2nd Annual Biosensors for Medical Wearables *In collaboration with Medical Design Briefs* 24th – 25th October 2022 | Boston, MA, USA Sponsored […]
The French delegation at BIO on June 13-16 has a compelling story to tell about biopharma and medtech growth and investment in France and the […]
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by […]
What You Should Know: – A new PwC report offers insights into how pharma companies can translate game-changing science into greater returns. – Despite many major therapeutic advancements within […]
What You Should Know: – Biotech company Phenomix Sciences launches its biobanking registry, marking the first obesity registry to study the impact of personalized treatment based on phenotyping. The […]
What You Should Know: – Pleno, a multi-omics startup, is emerging out of stealth with a $15M Pre-Series A financing and Greg Lucier as Chairman […]
What You Should Know: – Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. – Together they […]
Do you want to be part of the largest gathering of mRNA professionals? The 2nd Annual mRNA-Based Therapeutics Summit is returning in-person to Boston this July 26-28. Expect exclusive data from […]
The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the life sciences ecosystem. We […]
SAE Media Group’s 3rd Annual Wearable Injectors and Connected Devices Conference 10 – 11 October 2022 | London, UK http://www.wearable-injectors.co.uk/PharmaPhorum The Latest Innovations In Digital […]
What You Should Know: – Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding […]
Sudish Mogul, Chief Technology Officer of Healthcare Triangle Across life sciences, experts boldly predict that data is the new currency—and that mobilizing data from clinical […]
As artificial intelligence becomes more focused and efficient, and the pharmaceutical and biotech industries consolidate to survive, it’s important to also reflect on what is […]
The board of Eikon Therapeutics will soon look like Merck & Co’s a few years ago – after the big pharma’s former CEO Ken Frazier […]
What You Should Know: – VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series […]
The organisation behind the iconic Canary Wharf development has said it plans to build one of the largest commercial laboratory facilities in Europe as part […]
What You Should Know: – Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists […]
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient […]
Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development. […]
Hundreds of business leaders in the life sciences sector have added their names to an open letter that says they will cease all business dealings […]
Andrew Pucher, CEO of Dascena, Inc. One of the many acute challenges during the pandemic has been the departure of approximately 18% of the U.S. […]
What You Should Know: – This week, Definite Healthcare announced the acquisition of Analytical Wizards, an advanced analytics company revolutionizing analytics in healthcare by combining […]
The 3rd Protein Degradation and Targeting Undruggables Summit is North America’s only in-person, industry-led conference covering clinical progress and commercial scale development of first-in-class degrader […]
What You Should Know: – Today, Twist Bioscience and cancer genomics startup C2i Genomics announced a partnership to develop whole-genome cancer reference materials. – This […]
Read about news from Equiva, DNA Script, Healthmine, Infermedica, and more.
2021 was a record year for investments in UK biotech companies, consolidating the country’s position as one of Europe’s top life science hubs and apparently […]
Turbocharge the Development of Best-In-Class Treg-Directed Therapies, Maximising Stability and Function to Deliver Safe, Scalable and Efficacious Therapies Globally As Biopharma turn their focus to autoimmune drug […]
We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United […]
What You Should Know: Biotech R&D platform Benchling raises $100M at a $6B valuation, co-led by Franklin Templeton and Altimeter Capital to expand product development […]
Shots: The companies collaborated to develop cell line, drug substance, and drug product manufacturing of therapeutic and diagnostic mAbs directed against the immuno-oncology target oxMIF […]
Shots: The companies collaborated for CDx development of tepotinib in mainland China. The CDx test is based on Burning Rock’s OncoCompass target which is a […]
Shots: LCB to receive up front & milestone of ~$1027.5M upon achievement of development & regulatory milestones along with royalties on net sales. The deals […]
Shots: Entos will use its Fusogenix nucleic acid delivery system to develop BioMarin products for multiple genetic diseases. BioMarin will be responsible for the preclinical […]
Read news from Carrum Health, Healthmine, 1upHealth, and more.
Shots: Secarna to receive an upfront along with an option exercise fees & is also eligible to receive development & commercial milestone along with royalties […]
Shots: This agreement will expand Mustang’s pipeline of ex vivo lentiviral gene therapies for the treatment of SCID Lentiviral gene therapy is currently being evaluated […]
Shots: Dunad to receive $24M up front, equity investment, research funding & is eligible to receive ~$1.3B milestones along with royalties & will also be […]
Shots: Metagenomi to receive an up front, equity investment & is eligible to receive target option exercise fees in addition to development, regulatory, and commercial […]
Shots: Synthekine to receive up front along with an additional one-time payment, if selects a second target & will be eligible for ~$525M in development, […]
Shots: Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close […]
Shots: Ginkgo is eligible to receive up front, R& D fees including milestones in the form of Selecta common stock, clinical & commercial milestones of […]
Shots: Mammoth to receive $41M up front, $650M as future payments based upon the achievement of prespecified research, development & commercial milestones across 2 programs […]
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna […]
Shots: Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on […]
Shots: F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of […]
Shots: Beam to receive $50M up front & is eligible to receive a target option exercise fees, milestones upon achievement of development & sales milestones […]
Shots: The companies collaborated to evaluate the safety, PK & antiviral activity of ATI-2173, vebicorvir & TDF in an ongoing P-IIa ANTT201 trial in 10 […]
Shots: Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program The […]
Shots: The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver […]
Shots: Salipro to receive an up front, research payments and is eligible for a downstream milestones for several targets The collaboration will allow AbCellera to […]
Shots: Neumora has received a $100M as an equity investment and obtains an exclusive global right to develop and commercialize Amgen programs targeting casein kinase 1 delta […]
Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones […]
Shots: Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development […]
Shots: Xencor to receive $100M up front, $25M as an equity investment, ~$1.18B in milestones along with royalties on net sales of products that emerge […]
Shots: The companies terminated their collaboration that centered around bintrafusp alfa as the drug failed to show potential in INTR@PID Lung 037 study as the […]
Shots: Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & […]
Shots: Intract to receive an up front, development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & […]
The process of discovering HCPs who are leading key opinion leaders (KOLs) in emerging and growing markets is not as straightforward as it is in […]
Shots: VaxEquity can receive ~$195M in development, approval, and sales-based milestones along with royalties per program & is also eligible to receive an equity investment […]
Shots: The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza The preclinical […]
Shots: Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive […]
Shots: The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology The acquisition marks the […]
Shots: Gubra to receive ~ $253.4M as up front, development, and commercialization milestones The collaboration will combine Gubra’s peptide drug discovery capabilities with Bayer’s expertise […]
Shots: Coave to receive $11.7M up front & equity investment, ~ $76.5M as clinical development, regulatory & commercial milestones along with royalties on net sales […]
Shots: McGill to receive $350,000 up front, $10.5M as development and regulatory milestone & is also eligible for ~$30M as a commercial milestone. Clarus will […]
Shots: AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of […]
Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number […]
What You Should Know: – Lightstone Ventures today announced the closing of Lightstone Ventures III with $375M in capital commitments, to invest in early-stage companies […]
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – […]
Shots: The application is based on P-III CheckMate -648 study evaluating Opdivo (3mg/kg, q2w, IV) + Yervoy (1mg/kg, q6w up to 24mos.) or Opdivo + […]
Shots: Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with […]
After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. […]
Shots: Twist to receive an up front for each program and $710M in clinical, regulatory, and commercial milestones for the multiple target discovery programs Boehringer […]
Shots: ProQR to receive $20M up front, $30M as an equity investment & is also eligible to receive ~$1.25B as development, regulatory, and commercialization milestones […]
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular […]
Nordic Health Innovation: From realisation to business A virtual life science event with thought-provoking presentations, unexpected angles, future trends and pioneering ideas. The Nordic region […]
Shots: Adaptimmune to receive $150M up front, $150M as additional payments over 5yrs., $3B+ as research, development, regulatory & commercial milestones along with royalties across […]
Shots: NeuExcell is eligible to receive $190M up front, license fees, R&D, and sales milestones along with royalties Spark gets the option to license the […]
Shots: Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further […]
Shots: The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England The NICE recommendation […]
What You Should Know: Fresenius Medical Care (FMC) today announced its plans to invest an additional $25 million in clinical-stage biotechnology platform company Humacyte following the extension of […]
Shots: SpringWorks and Dana-Farber collaborated to evaluate nirogacestat with anti-B-cell maturation antigen (BCMA) agents in multiple preclinical multiple myeloma models SpringWorks will fund the work […]
Shots: ImmixBio to assess the safety, tolerability, and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors […]
Shots: Bolt to receive $5M up front in cash & $10M as an equity investment. Both companies will receive milestones & royalties on the development […]
Shots: NovaRock to receive $7.5M up front and is eligible to receive ~$633M as development & sales milestones along with royalties on the sales of […]
Shots: Lycia to receive $35M up front and is also eligible to receive an additional ~$1.6B upon the achievement of milestones along with royalties on […]
Shots: Arbor to receive an up front in cash & is eligible to receive an additional ~$1.2B on achievement of milestones across up to 7 […]
Shots: Shape is eligible to receive $3B+ including initial payment, development, regulatory, and sales milestone along with royalties on sales of therapies resulting from the […]
Shots: Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then […]
Shots: Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales BMS has […]
Michael Delisle, VP, Practice Leader for Digital Health at GattiHR Artificial Intelligence (AI) will disrupt healthcare’s destiny for good. Here are five steps digital health […]
In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They […]
Shots: Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible […]
Shots: Incyte to receive $35M up front & is eligible to receive an additional ~$82.5M as development, regulatory & commercial milestones along with royalties. The […]
Shots: RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of […]
Shots: AbbVie selects two DUB targets to advance it to the next stage of drug discovery based on the results from in vitro & in […]
Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights […]
Shots: Appia Bio to receive $875M as an up front, equity investment, and milestone along with royalties. Kite will be responsible for the development, manufacturing, […]
Shots: AstraZeneca to receive up front & development, regulatory and commercial milestones along with royalties. The agreement will provide a novel compound into Sierra’s pipeline […]
Shots: Schrödinger to receive up front to fund the share of research costs & is also eligible to receive ~$338M in pre/ clinical, regulatory & […]
Shots: AbCellera to receive milestones and royalties on products that are derived from its Ab discovery platform. Additionally, AbCellera has the option to invest in […]
Shots: Marinus to receive ~$30M up front & is eligible to receive ~$115M in R&D reimbursement milestone on achievement of clinical & commercialization milestones along […]
Shots: Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties, if […]
Shots: HilleVax gets an exclusive license for the development and commercialization rights of Takeda’s HIL-214 globally (Ex-Japan). Takeda will hold the commercialization rights of the […]
Shots: Minovia receives a $20M up front and is eligible to receive ~$420M per product in development, regulatory & commercial milestone for mitochondrial cell therapies […]
Shots: PeptiDream to receive an upfront along with R&D funding and may eligible for ~$2.2B in development, regulatory, and commercial milestones upon specified achievement along […]
Shots: Kumquat to receive an ~ $70M in upfront and an equity investment in addition to ~$2B in milestone based on the achievement of definite […]
Shots: Aristea to receive $60M as up front and $10M as equity investment in Aristea’s Series B financing. Arena gets an exclusive option to acquire […]
Shots: The collaboration will extend in 2022 for an additional 3yrs. Calico will lead R&D until 2025 & will advance projects into P-IIa through 2030 […]
Shots: As per expanded collaboration, PeptiDream to receive ~$3.5B as up front, preclinical, development, launch, and commercial milestones and is eligible to receive royalties on […]
Shots: BioNTech unveils the plan to develop the first mRNA-based vaccine to prevent malaria with anticipated initiation of the clinical study by the end of […]
Shots: The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen Biocon will gain rights to […]
Shots: Denali reports data from the P-I/II study evaluating DNL310 (qw, IV) for both CNS and peripheral MPS II. All patients received doses of DNL310 […]
Shots: RWE data from CIRN with support from the Public Health Agency of Canada and the Canadian Institutes of Health Research demonstrated that one dose […]
Shots: ImaginAb to receive license fees for providing ongoing technical, clinical, and regulatory support to facilitate the successful implementation of its CD8 ImmunoPET technology Following […]
Shots: Synaffix is eligible to receive $246M upfront & milestones along with royalties on net sales. ProfoundBio to get non-exclusive license rights to use Synaffix’s […]
Shots: Arbormentis to receive $51M upfront in cash and equity in addition to $150M as milestone related to pre-specified development and commercialization milestones along with […]
Shots: Kite will receive a one-time upfront to purchase Kite’s individualized solid tumor neoantigen TCR discovery platform, R&D & clinical manufacturing facility in Gaithersburg. The […]
Shots: AstraZeneca to receive $11M up front in cash and Aridis common stock. & will also receive ~ $115M upon the achievement of development and […]
Shots: The approval is based on seven P-II & III clinical studies involves assessing the safety, tolerability & immunogenicity of Vaxneuvance vs PCV13 in 7,438 […]
Shots: The collaboration is a part of the planned P-III TRAILBLAZER-ALZ 3 trial of donanemab vs PBO in patients with cognitive & functional decline related […]
Read about new developments from HealthMine, TailorMed, Heru and Entos.
Shots: Skyhawk collaborated with Aragen for the development of small molecule therapeutics that correct RNA expression Under the collaboration, Skyhawk will get multiple discovery chemistry […]
Shots: ProBioGen collaborates with Heat Biologics for both ProBioGen’s DirectedLuck Transposase System along with suspension HEK293 cell line The DirectedLuck Transposase is well-matched with additional […]
Shots: ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules The collaboration validates the immense clinical […]
Shots: Bicycle receives $45M as up front and is eligible to receive development, regulatory and commercial milestones along with royalties for each program developed under […]
Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s […]
Shots: The collaboration will evaluate the combination of Vor’s eHSC transplant platform with Janssen’s bi-specific Abs for the treatment of AML The agreement stated that […]
Shots: Verge to receive ~$25M as up front, equity investment, and near-term payments in addition to ~$694M as milestone and royalties The collaboration will utilize […]
Shots: F-star is eligible to receive up front and near-term payments of ~$12M & will be eligible for ~$300M as development & sales milestone along […]
Shots: The companies collaborated to evaluate BeiGene’s tislelizumab (anti-PD-1 immune checkpoint inhibitor) + PureTech’s LYT-200 (mAb targeting galectin-9) in patients with solid tumors associated with […]
Shots: The companies collaborated to evaluate Treos’ PolyPEPI1018 (Polypeptide cancer immunotherapy) + Roche’s atezolizumab (PD-L1-inhibitor) in P-I/II trial in patients with late-stage MSS mCRC which […]
Shots: The filing is based on the results from the P-III IMpower010 study assessing Tecentriq (1200mg, IV) vs BSC in 1,005 patients in a ratio […]
Shots: Eureka and MSK are eligible to receive up front and ~$1B as development, regulatory and sales milestone along with royalties on net sales. Sanofi […]
By KIM BELLARD I learned a new word this week: bioresorbable. It means pretty much what you might infer — materials that can be broken […]
Shots: Mimetas is eligible to receive up front and milestones while Roche will get an option to exclusively license specific disease models and assays for […]
A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in […]
The UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing in the three months to end-May – […]
Shots: Spero is eligible to receive $40M as an equity investment and ~$80M as development & sales milestones along with royalties on sales of SPR206 […]
Shots: NGM to receive ~ $120M as research & development funding through Mar’24, including ~$86M for the period from Apr’21 through Mar’22 & additional option […]
Shots: Alector to receive $700M as up front and is eligible to receive ~$1.5B as milestones. The companies collaborated to co-develop AL001 and AL101 for […]
Shots: Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be […]
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
Synthetic biology holds much promise for the life sciences sector as it continues to look for new ways of treating disease and accelerating drug development, […]
By MIKE MAGEE What will be the lasting impact of the Covid 19 pandemic? We still don’t know the answer to that question in full. […]
Shots: Lineage to receive an upfront payment in cash and, if the option is exercised, Lineage will be eligible for additional payments, including event-specific payments, […]
Shots: The first patient has been dosed in a P-II cancer vaccine trial evaluating the efficacy, tolerability & safety of BNT111 + Libtayo in combination […]
Read news from healthcare and life science companies including HealthMine, Zus Health, Sema4 and more.
Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in […]
Shots: The RELIEF study evaluating the efficacy & safety of VYEPTI (100mg, 30-minute IV infusion) vs PBO in a ratio (1:1) in 480 patients with […]
The growing pipeline of monoclonal antibodies, vaccines, enzymes, biosimilars and other therapeutic proteins have created an ever- increasing demand for highly- productive and stable cell […]
Shots: Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally, it is eligible to receive […]
Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on […]
Shots: The ongoing two P-I/ II studies, CLIMB-Thal-111 & CLIMB-SCD-121 evaluating CTX001 in 45 patients with a follow-up of ~2yrs. after infusion aged 18-35yrs to […]
Over time, several innovative technologies have been developed to support the designing and manufacturing of various types of antibody products; however, the aforementioned processes are […]
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will be held on the 28th – 29th of June, 2021 at the BGS online platform. CIOs and […]
Shots: The companies expanded their license agreement for the research and development of an additional gene therapy for a lysosomal storage disorder. Takeda has exercised […]
Shots: Shoreline to receive $45M up front in cash and is eligible to receive R&D funding, milestones along with royalties, following the achievement of certain […]
Shots: The partnership will utilize Novogene’s molecular diagnostics capabilities to expand patient identification by NGS in China for supporting the development of Hummingbird’s HMBD-001 which […]
Shots: Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and […]
Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World […]
Read about new developments from Stellar Health, Paige, venBio, and more.
J+D Forecasting has worked with one of Europe’s largest, leading biotechnology pioneers, helping to facilitate better, more collaborative forecasting for hundreds of colleagues across the continent. […]
The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of […]
Read about new developments from Blue Therapeutics, Docbot, Sema4, and Deep Lens.
Shots: BlueRock to get an option to license gene circuits emerging from the collaboration for cell therapy products in specific indications. If option exercises, the […]
Shots: BMS to get non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of a novel Ab combination therapy that is intended to […]
Shots: Boehringer Ingelheim has accepted a GalXC RNAi candidate (DCR-LIV2) for advancement under the existing agreement b/w the companies for the discovery and development of […]
Shots: Sarepta reported positive 12wks. expression & safety results from the first 11 participants enrolled in Study SRP-9001-103. The study uses commercially representative SRP-9001 Patients […]
Shots: Agenus to receive a $200M as up front & ~$1.36B as development, regulatory and commercial milestones plus royalties on net sales of the therapies. […]
Pre-commercial & Emerging pharma companies may not think they have the resources to match the launch strategies of big pharma. But with the proper planning […]
Shots: Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional […]
Shots: Biogen will utilize Envisagenics’ SpliceCore, an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types and […]
Shots: Pregene to receive $5M upfront and milestone for the 1st indication and $7.5M milestone for subsequent indications and is also eligible to receive $150M […]
Shots: The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 […]
Shota: MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties […]
Shots: Capsigen to receive $15M up front and is eligible to receive up to ~$42M as research milestones and ~$1.25B as additional payments upon the […]
Shots: The P-III POSEIDON study involves assessing Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment […]
Shots: AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs […]
Shots: Sanofi and Stanford Medicine collaborated to initiate three “deep-dive” research projects focusing on autoimmune diseases and inflammatory conditions The partners will organize a joint […]
UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready […]
Shots: Exelixis to acquire GamaMabs’ AMHR2 Ab technology for $5M and additionally payment upon achieving certain milestones. Following the closing of the transaction, Exelixis will […]
Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole […]
Shots: Repertoire and Yale University collaborated to understand the immunological causes of MS by identifying the specificity of various subsets of T cells The focus […]
Shots: BioMarin will receive an exclusive license to each program for research, development, and commercialization of the gene therapies The collaboration will utilize Allen institute […]
Shots: LogicBio to receive $10M up front with ~$581M as option payment and milestones along with royalties. Canbridge to get an exclusive option to license […]
Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI […]
Shots: Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of […]
The five life sciences IPOs this week continues the steady march companies are making to the public markets this year. This week’s activity follows a […]
Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across […]
In response to emailed questions, the CEO and CTO talk about the immune intelligence startups’ Human Immunity Map — a growing database of immune interactions […]
– Today Benchling, the leading life and sciences R&D cloud, announced a $200M Series E raise led by Sequoia Capital Global Equities and joined by […]
Shots: Senti Bio to receive up front and funding to support its research activities. If Spark exercises the option, Senti Bio will be eligible to […]
Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen talked about the formation of the company and its goal to make stem cell therapies accessible for […]
The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in […]
Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million). […]
UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that will be used to take its personalised […]
Shots: In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing […]
Shots: Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery, […]
Shots: In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo […]
With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress […]
With that in mind, the 3rd Cell Engager Summit (June 30 – July 1) is the only industry-led meeting focused on developing multi-specific cell engaging therapies in solid tumor indications, […]
Shots: The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both […]
Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize […]
Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration […]
– Today, Verily announced a partnership with Morehouse College in Atlanta, GA, to establish an endowed award of $575,000 to fund a new Verily Scholars Program. – […]
Shots: The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 […]
US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that […]
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of […]
Deborah Keller is a dynamic woman who gives off an immediate sense of warmth and humor. The moment she joined our video chat, she began […]
Deborah Keller is a dynamic woman who gives off an immediate sense of warmth and humor. The moment she joined our video chat, she began […]
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under […]
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under […]
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales […]
Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales […]
Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access […]
Shots: BioVectra to provide its integrated CDMO services for the manufacturing of API of bentracimab for use in PhaseBio’s ongoing global studies and global commercial […]
Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases […]
Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa […]
Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized […]
Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic […]
What You Should Know: – bene : studio, a San Francisco, CA-based global digital product consultancy, announced its non-equity, online HealthTech Product Accelerator, starting on […]
UK chancellor Rishi Sunak has been urged to recognise the leading role that pharma companies are playing in the economy in this week’s budget. Sunak […]
More healthcare startups are choosing to go public through mergers with special-purpose acquisition companies— publicly-traded shell companies created with the purpose of taking a private […]
Shots: The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders The focus of this agreement […]
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop […]
Shots: The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies Luminary gets a non-exclusive license for TcBuster and […]
Shots: Chugai gets exclusive development and commercializing rights for AT-527 in Japan Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to […]
US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out […]
Shots: Vir will receive ~$225M up front, $120M as an equity investment and $200M as regulatory milestones, ~300M as option payment and will be responsible […]
Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery […]
Shots: The multicenter survey involves assessing Kesimpta Sensoready autoinjector pen in 80 MS patients and 50 MS nurses, with RMS who received a disease modifying […]
Shots: The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor […]
Operation Warp Speed’s former science chief Moncef Slaoui is to lead research at a new mega-biotech called Centessa, formed by the merger of 10 privately-held […]
Shots: The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with […]
Disgraced investor Neil Woodford plans to start a new biotech investment firm as he seeks to capitalise on a booming UK life sciences industry and […]
Shots: Ensoma to receive $100M in up front & preclinical research payment, $10M in equity investment, and is eligible to receive $1.25B as development and […]
Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future […]
Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will […]
Shots: Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and […]
Copyright © 2024 | WordPress Theme by MH Themes